Clinical trials: Tamoxifen
Breast Cancer
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002646
- Testing
- fenretinide, tamoxifen citrate
- Where
- 85 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Eastern Cooperative Oncology Group
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
Osteoporosis, Postmenopausal
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
The purpose of this study is to compare treatment with both teriparatide and raloxifene with teriparatide alone. The study will evaluate any side effects that may be associated with the two drugs and may help to determine whether…
- Trial name
- NCT00046137
- Testing
- teriparatide, raloxifene
- Where
- 13 sites in United States
- Sponsor
- Eli Lilly and Company
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8
Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
- Trial name
- LoTam (NCT06671912)
- Testing
- Anastrozole, Letrozole, Exemestane
- Where
- 732 sites in United States, Puerto Rico
- Volunteers
- 1,556 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer, Recurrent Breast Cancer
Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer
Local treatment in addition to endocrine treatment as 1st line for oligo-metastatic ER-positive/HER2-negative breast cancer.
- Conditions
- Breast Cancer, Recurrent Breast Cancer, Stereotactic Body Radiotherapy, Estrogen Receptor Positive Tumor
- Trial name
- CLEAR (NCT03750396)
- Testing
- Surgical resection, Stereotactic body radiotherapy, Radiofrequency ablation
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Gangnam Severance Hospital
Prostate Cancer
Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy
Phase III clinical trial to study quality of life in prostate cancer patients by randomizing anti-androgen versus total androgen blockage prior to curative intended radiation therapy.
- Trial name
- NCT02382094
- Testing
- Bicalutamide
- Volunteers
- 110 people
- Sponsor
- Karolinska University Hospital
Postmenopause
Observational Study Analyzing RNA Expression Of Endometrial Biopsy Samples From Placebo, Bazedoxifene/Conjugated Estrogens And Raloxifene
This study is an observational study analyzing the biopsy samples collected from subjects that participated in Study 3115A1-303 (NCT00675688).
- Trial name
- NCT00847821
- Testing
- Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg
- Where
- 22 sites in United States
- Volunteers
- 185 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
The purpose of this study is to determine the efficacy and tolerability of 3 years treatment with anastrozole after a prior 2 years' treatment with tamoxifen versus 5 years treatment with tamoxifen in postmenopausal women with…
- Trial name
- ARNO-95 (NCT00287534)
- Testing
- Anastrozole, Tamoxifen
- Where
- 43 sites in Germany
- Volunteers
- 1,059 people
- Sponsor
- AstraZeneca
Neuroendocrine Tumors, Progesterone Receptor Positive Tumor
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
This is a single-arm, unicentric, single-stage clinical study of tamoxifen for patients with well differentiated neuroendocrine tumors and radiological progression with positive (> 1 percent) HR (estrogen and / or progesterone)…
- Conditions
- Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
- Trial name
- HORMONET (NCT03870399)
- Testing
- Tamoxifen
- Where
- 2 sites in United States, Brazil
- Volunteers
- 23 people
- Sponsor
- AC Camargo Cancer Center
Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized phase III trial to compare the effectiveness of tamoxifen with that of thalidomide in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer, Stage III Ovarian Epithelial Cancer
- Trial name
- NCT00041080
- Testing
- tamoxifen citrate, thalidomide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute (NCI)
Hodgkin's Disease, Breast Cancer
Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors
The purpose of this study is determine whether or not tamoxifen reduces the chance of Hodgkin's Disease survivors developing breast cancer.
- Trial name
- NCT00165308
- Testing
- Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
- Trial name
- NCT00482391
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Letrozole After Tamoxifen in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00003140
- Testing
- letrozole
- Where
- 57 sites in Canada, United Kingdom
- Volunteers
- 5,187 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors learn how well triptorelin given together with tamoxifen citrate or exemestane works in lowering estrogen levels.
- Trial name
- SOFT-EST (NCT00975676)
- Testing
- gas chromatography / tandem mass spectometry
- Where
- 24 sites in France, Hungary and 6 more
- Volunteers
- 123 people
- Sponsor
- ETOP IBCSG Partners Foundation
Stage I Breast Cancer, Stage II Breast Cancer
A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
- Trial name
- NCT01194427
- Testing
- Vorinostat and Tamoxifen
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thin Endometrium
Thin Endometrium Undergoing Frozen-thawed Embryo Transfer
The endometrium is essential for embryo implantation. The clinical pregnancy rate and live birth rate of patients with thin endometrium are significantly lower than those of normal endometrium.
- Trial name
- NCT04292886
- Testing
- Tamoxifen and femoston, Vitamin C and femoston
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanjing University
Osteoporosis
Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone Loss
To compare the effects of 2 years of lasofoxifene treatment with 2 years of raloxifene 60 mg/day use and 2 years of placebo use on bone mineral density (BMD) of the lumbar spine.
- Trial name
- CORAL (NCT00163137)
- Testing
- lasofoxifene, raloxifene
- Where
- 72 sites in United States
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Ligand Pharmaceuticals
Breast Cancer
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
The purpose of this study is to determine if the combination of endocrine therapy and Palbociclib at a daily dose of 100 mg will result in a better response to therapy with fewer dose interruptions than the proposed dosing…
- Trial name
- NCT02630693
- Testing
- Palbociclib 100mg, Palbociclib 125mg, Fulvestrant or Tamoxifen or Aromatase Inhibitor
- Where
- 22 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer, Osteoporosis
Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00107263
- Testing
- letrozole, zoledronic acid
- Volunteers
- 558 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00007904
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center